
    
      This two-year study will determine if daily oral intake of lipoic acid will prove superior to
      placebo in reducing injury to the brain and maintaining mobility in progressive MS. Mobility
      will be assessed with the timed 25-foot walk test and 2-minute timed walk test as well as
      fall counts. Neuroprotection will be measured by the extent of brain volume loss seen on MRI.
    
  